Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

22,083 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of KL-A167 in previously treated recurrent or metastatic nasopharyngeal carcinoma: a multicenter, single-arm, phase 2 study.
Shi Y, Qin X, Peng X, Zeng A, Li J, Chen C, Qiu S, Pan S, Zheng Y, Cai J, Chen X, Qu S, Lin L, Huang J, Wu H, Lu Y, Wang W, Hu C, He X, Yu Z, Liu X, Xie B, Liu A, Hu G, Jing S, Zhang Q, Guo R, Li Q, Hong J, Jin F, Meng J, Shi J, Wang P, Cui J, Yang K, Zhang X, Li X, Shen L, He Y, Zhai L, Sun X, Ge J, Qing Y, Zong D. Shi Y, et al. Among authors: lin l. Lancet Reg Health West Pac. 2022 Oct 10;31:100617. doi: 10.1016/j.lanwpc.2022.100617. eCollection 2023 Feb. Lancet Reg Health West Pac. 2022. PMID: 36879786 Free PMC article.
Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials.
Fang W, Yang Y, Ma Y, Hong S, Lin L, He X, Xiong J, Li P, Zhao H, Huang Y, Zhang Y, Chen L, Zhou N, Zhao Y, Hou X, Yang Q, Zhang L. Fang W, et al. Among authors: lin l. Lancet Oncol. 2018 Oct;19(10):1338-1350. doi: 10.1016/S1470-2045(18)30495-9. Epub 2018 Sep 10. Lancet Oncol. 2018. PMID: 30213452 Clinical Trial.
Association between Chinese Medicine Therapy and Survival Outcomes in Postoperative Patients with NSCLC: A Multicenter, Prospective, Cohort Study.
Wang XQ, Zhang Y, Hou W, Wang YT, Zheng JB, Li J, Lin LZ, Jiang YL, Wang SY, Xie Y, Zhang HL, Shu QJ, Li P, Wang W, You JL, Li G, Liu J, Fan HT, Zhang MY, Lin HS. Wang XQ, et al. Chin J Integr Med. 2019 Nov;25(11):812-819. doi: 10.1007/s11655-019-3168-6. Epub 2019 Aug 31. Chin J Integr Med. 2019. PMID: 31471834 Clinical Trial.
Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study.
Huang J, Xu J, Chen Y, Zhuang W, Zhang Y, Chen Z, Chen J, Zhang H, Niu Z, Fan Q, Lin L, Gu K, Liu Y, Ba Y, Miao Z, Jiang X, Zeng M, Chen J, Fu Z, Gan L, Wang J, Zhan X, Liu T, Li Z, Shen L, Shu Y, Zhang T, Yang Q, Zou J; ESCORT Study Group. Huang J, et al. Among authors: lin l. Lancet Oncol. 2020 Jun;21(6):832-842. doi: 10.1016/S1470-2045(20)30110-8. Epub 2020 May 13. Lancet Oncol. 2020. PMID: 32416073 Clinical Trial.
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial.
Zhou C, Chen G, Huang Y, Zhou J, Lin L, Feng J, Wang Z, Shu Y, Shi J, Hu Y, Wang Q, Cheng Y, Wu F, Chen J, Lin X, Wang Y, Huang J, Cui J, Cao L, Liu Y, Zhang Y, Pan Y, Zhao J, Wang L, Chang J, Chen Q, Ren X, Zhang W, Fan Y, He Z, Fang J, Gu K, Dong X, Zhang T, Shi W, Zou J; CameL Study Group. Zhou C, et al. Among authors: lin x, lin l. Lancet Respir Med. 2021 Mar;9(3):305-314. doi: 10.1016/S2213-2600(20)30365-9. Epub 2020 Dec 18. Lancet Respir Med. 2021. PMID: 33347829 Clinical Trial.
Efficacy, safety, and biomarker analysis of Camrelizumab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN study).
Yang Y, Zhou T, Chen X, Li J, Pan J, He X, Lin L, Shi YR, Feng W, Xiong J, Yang K, Yu Q, Zhang Q, Hu D, Sun Y, Hu G, Li P, Shen L, Lin Q, Zhang B, Qu X, Zou J, Zhang L, Fang W, Zhao Y. Yang Y, et al. Among authors: lin q, lin l. J Immunother Cancer. 2021 Dec;9(12):e003790. doi: 10.1136/jitc-2021-003790. J Immunother Cancer. 2021. PMID: 34933967 Free PMC article. Clinical Trial.
Multiplexed imaging of tumor immune microenvironmental markers in locally advanced or metastatic non-small-cell lung cancer characterizes the features of response to PD-1 blockade plus chemotherapy.
Wu F, Jiang T, Chen G, Huang Y, Zhou J, Lin L, Feng J, Wang Z, Shu Y, Shi J, Hu Y, Wang Q, Cheng Y, Chen J, Lin X, Wang Y, Huang J, Cui J, Cao L, Liu Y, Zhang Y, Pan Y, Zhao J, Wang L, Chang J, Chen Q, Ren X, Zhang W, Fan Y, He Z, Fang J, Gu K, Dong X, Zhang T, Shi W, Zou J, Bai X, Ren S, Zhou C; CameL Study Group. Wu F, et al. Among authors: lin x, lin l. Cancer Commun (Lond). 2022 Dec;42(12):1331-1346. doi: 10.1002/cac2.12383. Epub 2022 Nov 4. Cancer Commun (Lond). 2022. PMID: 36331328 Free PMC article.
Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309).
Yang Y, Pan J, Wang H, Zhao Y, Qu S, Chen N, Chen X, Sun Y, He X, Hu C, Lin L, Yu Q, Wang S, Wang G, Lei F, Wen J, Yang K, Lin Z, Guo Y, Chen S, Huang X, Wu Y, Liang L, Chen C, Bai F, Ma X, Zhang Y, Leaw S, Zhang L, Fang W. Yang Y, et al. Among authors: lin z, lin l. Cancer Cell. 2023 Jun 12;41(6):1061-1072.e4. doi: 10.1016/j.ccell.2023.04.014. Epub 2023 May 18. Cancer Cell. 2023. PMID: 37207654 Free article. Clinical Trial.
HLA-I Evolutionary Divergence Confers Response to PD-1 Blockade plus Chemotherapy in Untreated Advanced Non-Small Cell Lung Cancer.
Jiang T, Jin Q, Wang J, Wu F, Chen J, Chen G, Huang Y, Chen J, Cheng Y, Wang Q, Pan Y, Zhou J, Shi J, Xu X, Lin L, Zhang W, Zhang Y, Liu Y, Fang Y, Feng J, Wang Z, Hu S, Fang J, Shu Y, Cui J, Hu Y, Yao W, Li X, Lin X, Wang R, Wang Y, Shi W, Feng G, Ni J, Mao B, Ren D, Sun H, Zhang H, Chen L, Zhou C, Ren S. Jiang T, et al. Among authors: lin x, lin l. Clin Cancer Res. 2023 Dec 1;29(23):4830-4843. doi: 10.1158/1078-0432.CCR-23-0604. Clin Cancer Res. 2023. PMID: 37449971
Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial.
Xu RH, Shen L, Wang KM, Wu G, Shi CM, Ding KF, Lin LZ, Wang JW, Xiong JP, Wu CP, Li J, Liu YP, Wang D, Ba Y, Feng JP, Bai YX, Bi JW, Ma LW, Lei J, Yang Q, Yu H. Xu RH, et al. Among authors: lin lz. Chin J Cancer. 2017 Dec 22;36(1):97. doi: 10.1186/s40880-017-0263-y. Chin J Cancer. 2017. PMID: 29273089 Free PMC article. Clinical Trial.
22,083 results
You have reached the last available page of results. Please see the User Guide for more information.